Avadel Pharmaceuticals

8.76
0.16 (1.86%)
At close: Apr 25, 2025, 3:59 PM
8.77
0.17%
After-hours: Apr 25, 2025, 04:05 PM EDT

Avadel Pharmaceuticals Revenue Breakdown

Period Ending Jun 30, 2020 Mar 31, 2020 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017 Sep 30, 2016 Jun 30, 2016 Mar 31, 2016
Akovaz Revenue 4.2M 5.35M 4.21M 5.95M 3.79M 5.99M 11.88M 10.22M 18.56M 20.91M 25.64M 5.57M 25.62M 24.75M
Akovaz Revenue Growth -21.56% +27.12% -29.23% +56.80% -36.71% -49.55% +16.23% -44.95% -11.24% -18.43% +360.45% -78.27% +3.53% n/a
Bloxiverz Revenue 800K 1.4M 1.47M 2.36M 2.57M 3.66M 5.54M 7.49M 9.92M 13.72M 13.9M 15.59M 2.12M 1.2M
Bloxiverz Revenue Growth -42.90% -4.43% -37.83% -8.18% -29.76% -34.05% -25.99% -24.49% -27.69% -1.32% -10.83% +634.04% +77.00% n/a
Other Products Revenue 180K -21K -231K -160K 604K 373K 31K 1.83M 1.09M 2.32M 2.04M 841K 10.42M 9.41M
Other Products Revenue Growth -957.14% -90.91% +44.38% -126.49% +61.93% +1103.23% -98.30% +67.06% -52.89% +13.84% +142.33% -91.93% +10.79% n/a
Vazculep Revenue 4.92M 5.51M 8.79M 9.41M 9.47M 8.76M 11.38M 12.96M 9.57M 10.15M 10.18M 9.34M n/a n/a
Vazculep Revenue Growth -10.86% -37.24% -6.63% -0.67% +8.15% -23.01% -12.22% +35.39% -5.72% -0.25% +8.98% n/a n/a n/a

Revenue by Geography

Period Ending Dec 31, 2020 Dec 31, 2019 Dec 31, 2018 Dec 31, 2017 Dec 31, 2016 Dec 31, 2015
Ireland Revenue n/a n/a 1.85M 404K 2.96M 741K
Ireland Revenue Growth n/a -100.00% +356.93% -86.37% +299.87% n/a
United States Revenue 22.33M 59.22M n/a 172.84M 147.28M 172.38M
United States Revenue Growth -62.28% n/a n/a +17.35% -14.56% n/a

Operating Expense Breakdown

Period Ending Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017 Dec 31, 2016 Sep 30, 2016 Jun 30, 2016 Mar 31, 2016 Dec 31, 2015 Sep 30, 2015 Jun 30, 2015 Mar 31, 2015
Selling, General, and Administrative Revenue 40.39M 47.41M 48.62M 41.3M 39.16M 46.78M 24.47M 16.98M 14.1M 21.8M 21.64M 21.03M 21.28M 15.17M 11.01M 8.97M 8.42M 7.09M 7.91M 7.66M 5.32M 6.76M 10.45M 23.2M 24.83M 27.84M 24.49M 23.06M 11.56M 12.43M 11.81M 10.69M 12.74M 11.29M 9.46M 6.81M 4.57M 5.87M 4.46M
Selling, General, and Administrative Revenue Growth -14.79% -2.50% +17.73% +5.47% -16.29% +91.18% +44.09% +20.47% -35.35% +0.78% +2.90% -1.21% +40.26% +37.80% +22.71% +6.54% +18.72% -10.34% +3.26% +44.15% -21.34% -35.31% -54.97% -6.56% -10.82% +13.71% +6.20% +99.41% -6.97% +5.22% +10.52% -16.11% +12.84% +19.33% +38.97% +49.04% -22.22% +31.59% n/a
Research and Development Revenue 3.8M 4.05M 3.07M 2.36M 2.85M 4.22M 3.83M 6.24M 2.93M 4.54M 6.99M 2.11M 4.38M 6.76M 3.85M 5.29M 5.57M 4.06M 5.53M 7.76M 7.54M 10.29M 7.33M 6.09M 11.4M 11.89M 9.95M 12.13M 8.1M 6.79M 7.21M 13.48M 8.14M 7.6M 5.39M 5.16M 7.22M 7.2M 6.02M
Research and Development Revenue Growth -6.12% +32.04% +30.06% -17.20% -32.54% +10.26% -38.57% +112.58% -35.41% -35.05% +231.33% -51.83% -35.23% +75.55% -27.13% -5.08% +37.27% -26.64% -28.71% +2.89% -26.75% +40.43% +20.42% -46.62% -4.10% +19.49% -17.93% +49.78% +19.18% -5.75% -46.53% +65.49% +7.09% +41.13% +4.40% -28.53% +0.24% +19.63% n/a